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Abstract
Background
The liver fluke Opisthorchis viverrini infects several million people in Southeast Asia. Adult
flukes live in the bile ducts of humans, where they cause hepatobiliary pathology, including
cholangiocarcinoma. Here, we investigated the potential of extracellular vesicles (EVs)
secreted by the fluke and defined recombinant proteins derived from EVs to generate pro-
tective immunity in a hamster vaccination-challenge model.
Methodology/Principal findings
EVs isolated from the excretory-secretory products of O. viverrini and two recombinant EV
surface proteins encoding the large extracellular loops (LEL) of Ov-TSP-2 (rOv-TSP-2) and
Ov-TSP-3 (rOv-TSP-3) were adjuvanted and used to vaccinate hamsters intraperitoneally
followed by challenge infection with O. viverrini metacercariae. The number of adult flukes
recovered from hamsters immunized with EVs, rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2
+rOv-TSP-3 were significantly reduced compared to control animals vaccinated with adju-
vant alone. The number of eggs per gram feces was also significantly reduced in hamsters
vaccinated with rOv-TSP-2 compared to controls, but no significant differences were found
in the other groups. The average length of worms recovered from hamsters vaccinated with
EVs, rOv-TSP-2 and rOv-TSP-3 was significantly shorter than that of worms recovered from
the control group. Anti-EV IgG levels in serum and bile were significantly higher in hamsters
vaccinated with EVs compared to control hamsters both pre- and post-challenge. In
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addition, levels of anti-rOv-TSP antibodies in the serum and bile were significantly higher
than control hamsters both pre- and post-challenge. Finally, antibodies against rOv-TSP-2
and rOv-TSP-3 blocked uptake of EVs by human primary cholangiocyte in vitro, providing a
plausible mechanism by which these vaccines exert partial efficacy and reduce the intensity
of O. viverrini infection.
Conclusion/Significance
Liver fluke EVs and recombinant tetraspanins derived from the EV surface when adminis-
tered to hamsters induce antibody responses that block EV uptake by target bile duct cells
and exert partial efficacy and against O. viverrini challenge.
Author summary
Cholangiocarcinoma (CCA) is a significant public health problem in countries through-
out Southeast Asia. In these areas CCA has a strong association with chronic infection
with the food-borne liver fluke Opisthorchis viverrini. Current control of the infection
relies on chemotherapy and health education, however these approaches are not sustain-
able in isolation. Hence, there is an urgent need for a vaccine against this neglected tropi-
cal disease. A vaccine against O. viverrini would confer anti-cancer protection in similar
fashion to the acclaimed vaccine for human papillomavirus and cervical cancer. Toward
this goal, secreted extracellular vesicles (EVs) of O. viverrini and recombinant proteins
from the surface of EVs were generated and tested as vaccines in a hamster challenge
model. Vaccination of hamsters with EVs and recombinant proteins induced production
of antibodies in serum and bile, and those antibodies blocked uptake of EVs by primary
bile duct cells in vitro. Challenge of vaccinated hamsters with infective stage flukes
markedly reduced adult fluke recovery compared to the adjuvant control group. This is
the first report of successful vaccination of hamsters with O. viverrini EVs and recombi-
nant vesicle surface proteins, and provides proof-of-concept for development of subunit
vaccines for this carcinogenic infection.
Introduction
The human liver fluke Opisthorchis viverrini is endemic in different countries of Southeast
Asia including Thailand, Lao PDR, Cambodia, southern part of Vietnam and Myanmar [1, 2].
Furthermore, liver fluke infection is associated with a high incidence of liver pathology includ-
ing cholangiocarcinoma (CCA) [3, 4]. Current control efforts rely on drug treatment and
health education; however, they are not sustainable [5, 6]. Hence, it is essential to develop new
interventions for long-term protection against O. viverrini infection, and a vaccine approach
is an attractive strategy to reduce parasite burden and achieve ultimate eradication of the
parasite.
O. viverrini-induced hepatobiliary damage is multi-factorial, and includes several factors
such as mechanical damage of the epithelium by the suckers of the worm, secreted parasite
metabolites [7, 8] and different immunopathological processes [9]. The metabolic products of
O. viverrini are highly immunogenic and stimulate immunopathology [8], and include tegu-
mental and secreted proteins comprising more than 300 proteins [10]. In addition to secretion
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of soluble protein, we have previously reported that O. viverrini secretes exosome-like extracel-
lular vesicles (Ov-EVs) [11]. EVs are 40–100 nm in size and of endocytic origin; they are
enriched in various lipids, nucleic acids and proteins including tetraspanins, heat shock pro-
tein and actin [12]. O. viverrini tetraspanins (Ov-TSPs), belonging to both the CD9 and CD63
families, were found to be enriched in Ov-EVs and abundantly expressed on the outermost
tegument of adult worms [13, 14]. Ov-TSPs play an important role in dynamic host-parasite
interactions, particularly maintenance of tegument membrane integrity, and their suppression
using RNA interference results in a vacuolated tegument in vitro [13, 14]. EVs have been used
as protective vaccines in mouse models of intestinal helminths, including the nematodes, Tri-
churis muris [15] and Heligmosomoides polygyrus [16] and the trematode, Echinostoma caproni
[17]. Given the abundance of tetraspanins on the surface of fluke EVs [18, 19] and the ability
of antibodies against Ov-TSP-1 to block uptake of EVs by host cells [13], we propose that fluke
TSPs could be used as vaccines to interrupt host-parasite communication [20]. Moreover,
TSPs from the surface of schistosomes have proven to be efficacious vaccines in animal models
of blood fluke infection [21].
In the present study we assessed the vaccine potential of O. viverrini EVs and recombinant
Ov-TSPs derived from the EVs surface and the ability of antibodies from vaccinated animals to
block EVs uptake by host cells.
Materials and methods
Preparation of O. viverrini metacercariae
O. viverrini metacercariae were prepared as previously described [22]. Briefly, cyprinid fishes
from natural sources were homogenized with a blender and the homogenized fish was added
to pepsin solution (0.25% pepsin powder, 15% HCl in normal saline solution—NSS) at a ratio
of 1:3, followed by incubation at 37˚C for 1 hour to enable digestion. The digested solution
was filtered through 1,000, 300, and 106 μm meshes. The debris obtained by filtering with the
106 μm mesh was washed and repeatedly sedimented with NSS until clear. Sediments were
examined for metacercariae under a dissecting microscope. O. viverrini metacercariae were
collected and stored in sterile NSS at 4˚C until used.
Production of recombinant Ov-TSP-2 and -3 and rabbit antisera
The large extracellular loop (LEL) from Ov-TSP-2 and Ov-TSP-3 were recombinantly pro-
duced as fusions with thioredoxin (TRX) using the plasmid pET32a+ (Novagen, USA) in
Escherichia coli and purified as previously described [19]. New Zealand rabbits were immu-
nized with rOv-TSP-2 or -3 and antisera was collected as previously described [19].
Isolation of O. viverrini extracellular vesicles (Ov-EVs)
EVs were isolated from the excretory/secretory (ES) products released by adult O. viverrini
(OvES) as described previously with modifications [11, 23, 24]. Briefly, O. viverrini adult worms
were cultured in RPMI-1640 containing 1% glucose, antibiotics (Penicillin-Streptomycin
100 μg, Invitrogen, USA) and the 1 μM protease inhibitor E64 (Thermo Scientific, USA).
Worms were maintained in vitro at 37˚C and supernatants containing the OvES were collected
twice each day for up to 7 days and centrifuged at 2,090 g for 10 min to remove the eggs. OvES
was concentrated and buffer exchanged to 1x PBS using a 10 kDa cut-off purification column
(Amicon, Merk Millipore, USA). One (1) ml of concentrated OvES was centrifuged at 500 g,
2,000 g, 4,000 g and 12,000 g for 30 min each to remove cell debris. The supernatant was filtered
using a 0.22 μm filter (Sartorius, Germany), and subsequently pelleted by ultracentrifugation at
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110,000 g for 3 hours. The OptiPrep density gradient ultracentrifugation (ODG) was prepared
by diluting a 60% Iodixanol solution (Sigma Aldrich, USA) with 0.25 M sucrose in 10 mM Tris-
HCl, pH 7.2 to make 40%, 20%, 10% and 5% iodixanol solutions and then 1.0 ml of these solu-
tions was layered in decreasing density in an ultracentrifuge tube. Pelleted O. viverrini EVs (Ov-
EVs) were layered on top of the gradient and further centrifuged at 110,000 g for 18 h at 4˚C.
The fractions with a density of 1.12–1.24 g/mL were pooled and buffer exchanged to PBS using
100 kDa cut-off purification columns (Amicon, Merk Millipore, USA) and resuspended in
200 μl of PBS.
Vaccination and challenge of hamsters
Male Syrian golden hamsters 6–8 weeks-old were used for vaccination studies. Sample size was
calculated using two sample inference for comparing two means (https://www.stat.ubc.ca/~
rollin/stats/ssize/n2.html) [25]. A sample size of n = 9 was selected on the assumption of a vac-
cine trial resulting in a mean of 40 worms per hamster for μ1 (adjuvant control) and 25 worms
per hamster for μ2 (test group), σ = 11, two-sided test, with α = 0.05 and power of 0.80. A total
of 45 hamsters were divided into 5 groups (9 hamsters/group) including 1) vaccinated with
10 μg of Ov-EVs, 2) vaccinated with 50 μg of rOv-LEL-TSP-2, 3) vaccinated with 50 μg of rOv-
LEL-TSP-3, 4) vaccinated with 50 μg of rOv-LEL-TSP-2 plus 50 μg of rOv-LEL-TSP-3. Both
EVs and recombinant proteins were formulated with an equal volume of a colloidal suspension
of aluminium hydroxide gel (alum) (Invivogen, USA) and CpG ODN 1826 (10 μg) (Invivogen,
USA). A fifth group of hamsters were injected with 10 μg of alum/CpG only (adjuvant control
group) as a control group. Vaccines were injected intraperitoneally on days 0, 14 and 28; and
hamsters were challenged with 50 metacercariae via the oral route on day 42 (2 weeks after last
vaccination). Hamsters were finally sacrificed at 8 weeks post-challenge. Blood was collected
for serum by heart puncture after euthanasia and bile was collected from the gall bladder.
Whole livers were collected to investigate the number of flukes.
Faecal egg counts and worm recovery
Faeces from individual hamsters from each group were collected 6 weeks after challenge, and
eggs per gram feces (EPG) were counted and calculated using a modified formalin-ether acetate
technique [26]. Briefly, 2 grams of hamster feces were fixed in 10 ml of 10% formalin solution,
filtered through two layers of gauze, the filtered solution centrifuged at 500 g for 2 minutes, and
the supernatant discarded. The pellet was re-suspended with 7 ml of 10% formalin, vigorously
mixed with 3 ml ethyl acetate and then centrifuged at 500 g for 5 minutes. The pellet was dis-
solved in 1 ml of 10% formalin solution and examined in duplicate under light microscopy at
400x magnification. EPG was calculated as follows: (average of number eggs x total drops of
fecal solution)/ g of feces. Whole livers from the hamsters were dissected in NSS and adult
worms were collected and counted. The percent reduction of worm recovery was calculated as
previously described [27]: % Worm reduction = ((Wc–We) / Wc) x 100 (Wc = worm burden in
control group, We = worm burden in experiment group). To measure worm length, 21.4–42.2%
of the total worms recovered from each group were randomly selected. Worms were washed
three times with NSS and fixed in pre-warmed 10% formalin. Worms were photographed under
microscopy and worm length was measured using NIS-Element software (Nikon, Japan).
Indirect ELISA for specific IgG
Specific IgG against rOv-TSP-2, rOv-TSP-3, OvES, or Ov-EVs was measured in the serum and
bile by indirect ELISA. Hamster serum and bile were collected as described above. Polystyrene
flat bottom96-well ELISA plates (NUNC-F96, Fisher Scientific, USA) were coated with 100 μl
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of rOv-TSP-2 or rOv-TSP-3 or OvES (1 μg/ml) or Ov-EVs (2 μg/ml) overnight at 4˚C in coat-
ing buffer (0.05 M Na2CO3/NaHCO3, pH 9.6). Plates were washed with PBS 0.05% Tween-20
(PBST) and, then, blocked with 200 μl 5% skim milk in PBST for 2 hours at 37˚C. One hun-
dred (100) μl of sera (1:2,000 in PBST/2% skim milk) or bile (1:200 in PBST/2% skim milk)
were added and incubated for 2 hours at 37˚C. The plates were washed with PBST and probed
with 100 μl of anti-hamster IgG conjugate HRP (BioRad, USA) (1:2000 in PBST for serum and
1:1,000 for bile). After washing with PBST, the plates were developed by adding 50 μl TMB
(Thermo Fisher Scientific, USA) for 20 minutes, and reaction was stopped by adding 50 μl of
2N H2SO4. The colorimetric reaction was read at a wavelength of 450 nm on a Spectra Max
microplate reader (Molecular Devices, USA).
Western blot
Five (5) μg of OvES, OvEVs, OvES depleted of OvEVs, rOv-TSP-2 and rOv-TSP3 were loaded
and electrophoresed in a 15% SDS-PAGE gel and proteins were transferred to a nitrocellulose
membrane (Mini Trans-Blot Cell, Bio-Rad, USA). Membranes were probed with vaccinated
hamster serum (1:200) by incubation at 4˚C overnight followed by incubation with anti-ham-
ster IgG-HRP (1:1,000) at 25˚C for 2 h. The reaction color was developed by adding Luminata
Forte Western HRP Substrate (Millipore, USA).
Blocking of O. viverrini EVs internalization by host cells
Five (5) μg of Ov-EVs were labeled with PKH67 (Sigma-aldrich, USA) following the manufac-
turer’s instructions and incubated with anti-Ov-TSP-2 or -TSP-3 rabbit sera [19], with vacci-
nated hamster sera (Ov-TSP-2, Ov-TSP-3, Ov-TSP-2 plus -3 and Ov-EVs) or with control sera
(adjuvant alone) at a 1:2.5 dilution for 1 hour at room temperature. Ov-EVs-antibody com-
plexes were washed by 1x PBS using 100 kDa cut-off purification columns (Amicon, Merk
Millipore, USA) and cultured with H69 cells for 2 hours. Nuclei were stained with 2 μg/ml of
Hoechst (Invitrogen, USA) for 15 minutes. The image was taken using a Carl Zeiss confocal
microscope (LSM800, USA) at 200x of the original magnification. Thirty cells from 2 biologi-
cal replicates were analyzed for fluorescence intensity using imageJ version 1.50i.
Statistical analysis
All data are represented as mean ± SD of three independent experiments using Graphpad
Prism Software Version 6.03 (www.graphpad.com). Data from worm burden, EPG, worm
length, ELISA experiments and fluorescence intensity were evaluated by Student’s t-test.
Ethics statement
Male Syrian (golden) hamsters (Mesocricetus auratas) were reared at the animal facilities of the
Faculty of Medicine, Khon Kaen University. Experimentation protocols were approved by the
Animal Ethics Committee of Khon Kaen University according to the Ethics of Animal Experi-
mentation of the National Research Council of Thailand, with the approval number ACUC
KKU 10/2559.
Results
O. viverrini tetraspanin antibodies inhibit internalization of Ov-EVs by
human cholangiocytes
H69 human cholangiocytes actively internalize Ov-EVs [11]. Co-culture of fluorescently
labeled Ov-EVs with antisera from rabbits vaccinated with rOv-TSP-2 and rOv-TSP-3 resulted
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in 91% (����P<0.0001) and 77% (����P<0.0001) reductions respectively in uptake of EVs by
cells compared to control cells that were cultured with pre-immunization rabbit serum (Fig 1).
IgG levels in the serum and bile of hamsters vaccinated with Ov-EVs and
rOv-TSPs
Hamsters vaccinated with Ov-EVs showed a significant increase in serum IgG against OvES
(Fig 2A) and Ov-EVs (Fig 2B) when compared with pre-immunization sera and sera from the
adjuvant control group (P<0.0001). On the other hand, the IgG levels against OvES post-vacci-
nation but pre-challenge in hamsters vaccinated with rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2
+rOv-TSP-3 were not statistically significant compared to the adjuvant control group (S1 Fig).
The total serum IgG against rOv-TSP-2 in hamsters immunized with rOv-TSP-2 and rOv-
TSP-2+rOv-TSP-3 was significantly higher at pre-challenge and post-challenge compared to
pre-immunization and adjuvant control sera (P<0.0001) (Fig 2C).
Fig 1. Ov-TSP antisera blocks O. viverrini EVs internalization by human cholangiocytes. PKH67-labeled Ov-EVs were incubated with
rabbit antisera to rOv-TSP-2 or rOv-TSP-3 or pre-immunization serum prior to co-culture with H69 cholangiocytes. Panel A = rabbit pre-
immunization serum, panel B = rabbit antiserum to rOv-TSP-2 1:2.5, panel C = rabbit antiserum to rOv-TSP-3 1:2.5. Panel D shows
fluorescence intensity at 490 nm (green channel). The nuclei were stained by Hoechst (blue color) (���� P<0.0001).
https://doi.org/10.1371/journal.pntd.0007450.g001
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Likewise, the serum IgG against rOv-TSP-3 levels in hamsters immunized with Ov-EVs,
rOv-TSP-3 or rOv-TSP-2+rOv-TSP-3 were significantly higher pre- and post-challenge than
pre-immunization and adjuvant control sera (P<0.0001) (Fig 2D).
Total bile IgG against OvES was significantly higher post-vaccination but pre-challenge in
hamsters vaccinated with Ov-EVs (P< 0.05), rOv-TSP-2 (P<0.01) and rOv-TSP-2+rOv-TSP-3
(P<0.01) when compared with adjuvant control bile, while IgG levels in post-challenge sam-
ples were significantly higher in rOv-TSP-2 (P<0.001) and rOv-TSP-2+rOv-TSP-3 (P<0.0001)
vaccinated groups than in the adjuvant group (Fig 3A).
IgG levels against rOv-TSP-2 in the bile of hamsters immunized with rOv-TSP-2 and rOv-
TSP-2+rOv-TSP-3 were significantly higher than bile IgG from the adjuvant control group
(Fig 3B). Furthermore, the IgG levels in the bile of rOv-TSP-2+rOv-TSP-3 vaccinated animals
were significantly (P<0.05) higher at pre-challenge and post-challenge compared to the same
samples from the adjuvant group. In the Ov-EVs vaccinated group, bile IgG levels against rOv-
TSP-2 post-challenge were higher than those obtained pre-challenge (P<0.05) and in the adju-
vant control groups, but these differences did not reach significance (Fig 3B).
IgG antibody levels in bile against rOv-TSP-3 were not statistically different in the pre-chal-
lenge or post-challenge samples in any group when compared to the adjuvant group (Fig 3C).
Fig 2. Serum IgG levels in vaccinated hamsters. Serum IgG was measured from hamsters immunized with Ov-EVs,
rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3 at pre-immunization, pre-challenge and post-challenge. The IgG
levels were measured against OvES (A), Ov-EVs (B), rOv-TSP-2 (C) and rOv-TSP-3 (D). Results represent the mean
absorbance measured at 450 nm for each group. Significant differences are denoted by an asterisk over the bar (����
P<0.0001).
https://doi.org/10.1371/journal.pntd.0007450.g002
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Vaccination with Ov-EVs and Ov-TSPs decreased worm burden in
hamsters challenged with O. viverrini
Hamsters immunized with Ov-EVs, rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3 had
significantly lower worm burdens than the control group post-challenge (P<0.05) (Fig 4A).
The number of worms was reduced by 27% (P<0.05), 34% (P<0.01), 30% (P<0.001) and 21%
(P<0.001) respectively when compared with the adjuvant control group (Fig 4A). Further-
more, mean EPG in hamsters vaccinated with Ov-EVs and rOv-TSP-2 were reduced by 32%
(P<0.01) and 41% (P<0.001) respectively compared to the adjuvant control group (Fig 4B).
Vaccination with rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3 had no effect on EPG when com-
pared with the control group (Fig 4B).
Growth retardation of worms recovered from hamsters vaccinated with
Ov-EVs and rOv-TSPs
The body length of recovered worms from hamsters vaccinated with Ov-EVs, rOv-TSP-2, rOv-
TSP-3 and rOv-TSP-2+rOv-TSP-3 was significantly (P<0.001) shorter than worms recovered
Fig 3. IgG levels in bile of vaccinated hamsters. Bile IgG was measured by ELISA at pre-challenge and post-challenge against
OvES (A), rOv-TSP-2 (B) and rOv-TSP-3 (C). Results represent the mean absorbance measured at 450 nm for each group.
Significant differences are denoted by an asterisk over the bar (���� P<0.0001, ��� P<0.001, �� P<0.01, � P<0.05).
https://doi.org/10.1371/journal.pntd.0007450.g003
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from the control adjuvant group (Fig 5A). The average length of examined worms from ham-
sters vaccinated with Ov-EVs, rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3 was 2.92
±0.55, 2.93±0.50, 3.01±0.61, 2.82 ±0.51 mm, respectively while the average length of worms
from control adjuvant group was 33.89±0.77 mm. A representation of the morphology of the
worms from each group is shown in Fig 5B.
Sera from vaccinated hamsters recognize O. viverrini proteins
OvES, OvES depleted of EVs (dEVs), rOv-TSP-2 and rOv-TSP-3 were probed with a pooled
serum from each group of vaccinated hamsters by western blot. OvES was only detected by
pre-challenge serum from the Ov-EVs vaccinated group. The rOv-TSP-2 protein was detected
by pooled sera from pre-challenge hamsters vaccinated with rOv-TSP-2, rOv-TSP-3 and rOv-
TSP-2+rOv-TSP-3, while the rOv-TSP-3 protein was recognized by pooled sera from hamsters
vaccinated with Ov-EVs, rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3. As expected,
none of the samples were detected by pooled serum from hamsters vaccinated with adjuvant
alone (S2A Fig). Post-challenge sera from all vaccinated groups reacted against all samples
(OvES, rOv-TSP-2, rOv-TSP-3, dEVs and Ov-EVs), indicating that the native extracts (OvES
and EVs) as well as recombinant TSP-2 and TSP-3 are immunogenic in the course of a natural
infection (S2B Fig).
Antibodies of vaccinated hamsters block uptake of Ov-EVs by host cells
PKH67-labelled Ov-EVs were incubated with pooled sera of hamsters vaccinated with rOv-
TSP-2, rOv-TSP-3, rOv-TSP-2+rOv-TSP-3, Ov-EVs and from the control groups at a dilution
of 1:2.5 before being cultured with H69 cholangiocytes. Ov-EVs uptake was significantly
reduced more than 77% and 72% after incubation with rOv-TSP-2 and rOv-TSP -3 vaccinated
Fig 4. Vaccinated hamsters have significantly fewer worms than control animals. Panel A, Worm burden from each hamster and worm reduction rate in
hamsters vaccinated with O. viverrini EVs (Ov-EVs), rOv-TSP-2, rOv-TSP-3 and rOv-TSP-2+rOv-TSP-3 and control alum/CpG (adjuvant). �� P<0.01, ���
P<0.001, ���� P<0.0001. Panel B = Number of eggs per gram of feces (EPG) from each vaccinated hamster with mean and SD bar shown (�� P<0.01, ���
P<0.001).
https://doi.org/10.1371/journal.pntd.0007450.g004
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hamster serum, respectively (Fig 6C, 6D and 6G) when compared with pre-immunization
serum and serum from the adjuvant group (Fig 6A). Likewise, antisera to rOv-TSP-2+rOv-
TSP-3 and antisera to Ov-EVs blocked Ov-EVs internalization by cholangicytes by more than
80% (Fig 6E, 6F and 6G).
Discussion
The presence of EVs in OvES products precipitated the hypothesis that these vesicles are
important in host-parasite communication and immunopathogenesis [11]. EVs have also been
characterized in others trematodes such as Echinostoma caproni [28], Fasciola hepatica [29]
and Schistosoma spp. [18, 30, 31]. Moreover, other helminths such as the gastrointestinal nem-
atodes H. polygyrus [16, 32] and N. brasiliensis [33] also secrete EVs enriched in specific pro-
teins and miRNAs and can suppress the immunological response in vivo.
In the present study we have shown that immunization of hamsters with Ov-EVs reduced
both worms burden and egg production, and that IgG antibody levels specific to Ov-EVs were
significantly raised in serum and in bile of vaccinated hamsters. The development of the adult
parasites was significantly hampered in hamsters vaccinated with Ov-EVs, as demonstrated by
stunted parasite growth in vaccinated hamsters. Other groups have also studied the ability of
EVs to control trematode and other helminth infections. For instance, purified EVs from Echi-
nostoma caproni used to vaccinate mice prior to parasite challenge resulted in elevated anti-
body (IgG) responses but vaccination did not reduce the number of adult worms in the gut
Fig 5. Significant stunting is evident in worms recovered from vaccinated animals. The body length of 21.4–42.2%
of randomly selected worms recovered from each experimental group of vaccinated hamsters was measured using the
NIS-element program (A). Flukes from vaccinated animals were significantly shorter than those from hamsters that
received adjuvant alone (B).
https://doi.org/10.1371/journal.pntd.0007450.g005
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after challenge infection [17]. Vaccination of mice with EVs from the nematode H. polygyrus
resulted in worm reduction of 82% [16].
The use of native helminth EVs as vaccines is not feasible due to the difficulty in culturing
sufficient numbers of worms to collect the required amount of EVs material, however the util-
ity of sera from EVs-vaccinated animals as a discovery tool is evident. With that in mind, we
reasoned that proteins that are abundant on the surface of Ov-EVs might impart protective
immunity by blocking fluke EVs-host cell interactions. To our knowledge, this is the first
report of vaccination with recombinant proteins specifically aimed at inducing antibodies
against EVs surface proteins and subsequent blocking of EVs uptake by host cells.
Fig 6. Sera from hamsters vaccinated with rOv-TSPs block O. viverrini EV internalization by host cholangiocytes. PKH67
labeled Ov-EVs was incubated with hamster antisera to rOv-TSP-2 or rOv-TSP-3 or rOv-TSP-2+rOv-TSP-3 or adjuvant or pre-
immunization prior to co-culture with H69 cholangiocytes. Panel A = hamster pre-immunized serum, panel B = Adjuvant hamster
serum, panel C = hamster antiserum to rOv-TSP-2, panel D = hamster antiserum to rOv-TSP-3, panel E = hamster antiserum to
rOv-TSP-2 plus -3 and panel F = hamster antiserum to Ov-EVs. Panel G shows fluorescence intensity of internalization at 490 nm
(green channel). The nuclei were stained by Hoechst (blue color) (���� P<0.0001).
https://doi.org/10.1371/journal.pntd.0007450.g006
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Ov-TSP-2 and Ov-TSP-3 are members of the CD63 family of tetraspanins and have been
shown to be abundantly expressed in the O. viverrini tegument as well as enriched in Ov-EVs
[11]. Vaccination of hamsters with rOv-TSP-2 and rOv-TSP-3 strong IgG responses that were
readily detectable in both sera and bile–the fluid surrounding adult flukes in the biliary tract.
The presence of specific IgG in the bile might be a result of diffusion from the blood vessels
into the gall bladder where they impact on resident flukes. Previous vaccine studies have used
crude O. viverrini antigens to immunize hamsters prior to challenge with metacercariae [6],
but to our knowledge this is the first report of successful vaccination of hamsters with O. viver-
rini recombinant antigens. The utility of tetraspanins as helminth vaccines is evident in schis-
tosomiasis where Sm-TSP-2 is one of the leading vaccine candidates for a human
schistosomiasis vaccine [21] and has recently completed phase 1 clinical trials [34].
Antibodies against proteins specific to the Ov-EVs membrane such as the TSPs from sera
from vaccinated animals (pre-challenge) significantly blocked EVs internalization by cholan-
giocytes. These antibodies might block the ability of the parasite to communicate with its host,
thereby impairing the establishment and growth of the parasite by interrupting its ability to
suppress inflammation. Worms recovered from vaccinated animals were stunted, supporting
this hypothesis. It has been previously shown that blocking Ov-EVs internalization decreases
the levels of IL-6 (a cytokine heavily implicated in the development of fibrosis) and cell prolif-
eration [11]. We suggest that antibodies specific to the Ov-EVs surface may be performing
neutralizing roles by blocking the ability of fluke EVs to hijack host cholangiocytes and inter-
fere with induction of wound healing processes that repair damaged biliary tissue [35, 36] and
promote long-term survival of the flukes. Clearly, other molecular mechanisms that are inde-
pendent of EVs are utilized by liver flukes to communicate with their hosts, including proteins,
peptides, glycans and lipids that direct interact with host cells [37].
In contrast to our findings reported herein where antibodies to EV surface TSPs block
uptake of vesicles by cholangiocytes, a recent report described enhanced uptake by macro-
phages of F. hepatica EVs in the presence of antibodies against a CD63-like TSP on the vesicle
surface [38]. This is likely due to opsonisation of EVs and FcR-mediated uptake by antigen
presenting cells [16, 38] as opposed to distinct EV uptake by non-phagocytic target cells such
as cholangiocytes that we describe herein.
In summary, immunization with rOv-TSP-2 and Ov-EVs elicit robust antibody responses
which is key for protection against fluke infection, resulting in reduction of worms and egg
burden. Moreover, antibodies produced against rOv-TSP-2 significantly blocked internaliza-
tion of Ov-EVs by cholangiocytes. The tetraspanin proteins present in the membrane of EVs
are key in cell contact and uptake [39], and impairing this interaction could be blocking
important host-parasite interactions affecting the survival of the parasite. This is the first study
to determine the vaccine efficacy of Ov-EVs or the recombinant tetraspanins rOv-TSP-2 and
rOv-TSP-3 against a challenge infection with metacercariae of O. viverrini in hamsters, and it
supports the notion that targeting interactions between fluke EVs and their mammalian host
cells holds promise for the discovery of novel vaccine candidates.
Supporting information
S1 Fig. Serum IgG against Ov-ES of vaccinated hamsters. ELISA showing IgG levels against
Ov-ES of pre-immunized, pre-challenge or post-challenge hamster sera from each vaccinated
group.
(TIF)
S2 Fig. Western blot analysis of the recognition of O. viverrini proteins by sera from vacci-
nated hamsters. OvES, rOv-TSP-2, rOv-TSP-3, Ov-ES-depleted EVs (dEVs) and Ov-EVs were
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probed with pre-challenge hamster sera (A) or post-challenge hamster sera from each vaccina-
tion group (B).
(TIF)
Acknowledgments
We thank laboratory staffs of the Department of Parasitology and Tropical Disease Research
Laboratory, Department of Pathology, Faculty of Medicine, Khon Kaen University for techni-
cal supports.
Author Contributions
Conceptualization: Sujittra Chaiyadet, Alex Loukas, Thewarach Laha.
Formal analysis: Javier Sotillo.
Funding acquisition: Paul J. Brindley, Alex Loukas, Thewarach Laha.
Methodology: Sujittra Chaiyadet, Javier Sotillo, Watchara Krueajampa, Sophita Thongsen.
Resources: Paul J. Brindley, Banchob Sripa.
Supervision: Alex Loukas, Thewarach Laha.
Writing – original draft: Sujittra Chaiyadet, Javier Sotillo.
Writing – review & editing: Alex Loukas, Thewarach Laha.
References
1. Sithithaworn P, Andrews RH, Nguyen VD, Wongsaroj T, Sinuon M, Odermatt P, et al. The current status
of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitology international. 2012; 61(1):10–6.
Epub 2011/09/07. https://doi.org/10.1016/j.parint.2011.08.014 PMID: 21893213; PubMed Central
PMCID: PMC3836690.
2. Aung WPP, Htoon TT, Tin HH, Thinn KK, Sanpool O, Jongthawin J, et al. First report and molecular
identification of Opisthorchis viverrini infection in human communities from Lower Myanmar. PloS one.
2017; 12(5):e0177130. Epub 2017/05/05. https://doi.org/10.1371/journal.pone.0177130 PMID:
28472153; PubMed Central PMCID: PMC5417708.
3. Sriamporn S, Pisani P, Pipitgool V, Suwanrungruang K, Kamsa-ard S, Parkin DM. Prevalence of
Opisthorchis viverrini infection and incidence of cholangiocarcinoma in Khon Kaen, Northeast Thailand.
Tropical medicine & international health: TM & IH. 2004; 9(5):588–94. Epub 2004/05/01. https://doi.org/
10.1111/j.1365-3156.2004.01234.x PMID: 15117303.
4. Khuntikeo N, Titapun A, Loilome W, Yongvanit P, Thinkhamrop B, Chamadol N, et al. Current Perspec-
tives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia. Frontiers in
medicine. 2018; 5:117. Epub 2018/05/17. https://doi.org/10.3389/fmed.2018.00117 PMID: 29765958;
PubMed Central PMCID: PMC5938629.
5. Soukhathammavong P, Odermatt P, Sayasone S, Vonghachack Y, Vounatsou P, Hatz C, et al. Efficacy
and safety of mefloquine, artesunate, mefloquine-artesunate, tribendimidine, and praziquantel in
patients with Opisthorchis viverrini: a randomised, exploratory, open-label, phase 2 trial. Lancet Infect
Dis. 2011; 11(2):110–8. Epub 2010/11/30. https://doi.org/10.1016/S1473-3099(10)70250-4 PMID:
21111681.
6. van den Enden E. Pharmacotherapy of helminth infection. Expert Opin Pharmacother. 2009; 10
(3):435–51. Epub 2009/02/05. https://doi.org/10.1517/14656560902722463 PMID: 19191680.
7. Harinasuta T, Riganti M, Bunnag D. Opisthorchis viverrini infection: pathogenesis and clinical features.
Arzneimittelforschung. 1984; 34(9B):1167–9. Epub 1984/01/01. PMID: 6542384.
8. Sripa B, Brindley PJ, Mulvenna J, Laha T, Smout MJ, Mairiang E, et al. The tumorigenic liver fluke
Opisthorchis viverrini—multiple pathways to cancer. Trends Parasitol. 2012; 28(10):395–407. Epub
2012/09/06. https://doi.org/10.1016/j.pt.2012.07.006 PMID: 22947297; PubMed Central PMCID:
PMC3682777.
Vaccination of hamster with extracellular vesicles and tetraspanins from liver fluke
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007450 May 28, 2019 13 / 15
9. Haswell-Elkins MR, Sithithaworn P, Mairiang E, Elkins DB, Wongratanacheewin S, Kaewkes S, et al.
Immune responsiveness and parasite-specific antibody levels in human hepatobiliary disease associ-
ated with Opisthorchis viverrini infection. Clin Exp Immunol. 1991; 84(2):213–8. Epub 1991/05/01.
https://doi.org/10.1111/j.1365-2249.1991.tb08151.x PMID: 2025950; PubMed Central PMCID:
PMC1535388.
10. Mulvenna J, Sripa B, Brindley PJ, Gorman J, Jones MK, Colgrave ML, et al. The secreted and surface
proteomes of the adult stage of the carcinogenic human liver fluke Opisthorchis viverrini. Proteomics.
2010; 10(5):1063–78. Epub 2010/01/06. https://doi.org/10.1002/pmic.200900393 PMID: 20049860;
PubMed Central PMCID: PMC3038172.
11. Chaiyadet S, Sotillo J, Smout M, Cantacessi C, Jones MK, Johnson MS, et al. Carcinogenic Liver Fluke
Secretes Extracellular Vesicles That Promote Cholangiocytes to Adopt a Tumorigenic Phenotype. J
Infect Dis. 2015; 212(10):1636–45. Epub 2015/05/20. https://doi.org/10.1093/infdis/jiv291 PMID:
25985904; PubMed Central PMCID: PMC4621255.
12. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol.
2013; 200(4):373–83. Epub 2013/02/20. https://doi.org/10.1083/jcb.201211138 PMID: 23420871;
PubMed Central PMCID: PMC3575529.
13. Chaiyadet S, Smout M, Laha T, Sripa B, Loukas A, Sotillo J. Proteomic characterization of the internali-
zation of Opisthorchis viverrini excretory/secretory products in human cells. Parasitol Int. 2017; 66
(4):494–502. Epub 2016/02/14. https://doi.org/10.1016/j.parint.2016.02.001 PMID: 26873540; PubMed
Central PMCID: PMC5149449.
14. Piratae S, Tesana S, Jones MK, Brindley PJ, Loukas A, Lovas E, et al. Molecular characterization of a
tetraspanin from the human liver fluke, Opisthorchis viverrini. PLoS neglected tropical diseases. 2012; 6
(12):e1939. Epub 2012/12/14. https://doi.org/10.1371/journal.pntd.0001939 PMID: 23236532; PubMed
Central PMCID: PMC3516575.
15. Shears RK, Bancroft AJ, Hughes GW, Grencis RK, Thornton DJ. Extracellular vesicles induce protec-
tive immunity against Trichuris muris. Parasite immunology. 2018; 40(7):e12536. Epub 2018/05/11.
https://doi.org/10.1111/pim.12536 PMID: 29746004; PubMed Central PMCID: PMC6055854.
16. Coakley G, McCaskill JL, Borger JG, Simbari F, Robertson E, Millar M, et al. Extracellular Vesicles from
a Helminth Parasite Suppress Macrophage Activation and Constitute an Effective Vaccine for Protec-
tive Immunity. Cell reports. 2017; 19(8):1545–57. Epub 2017/05/26. https://doi.org/10.1016/j.celrep.
2017.05.001 PMID: 28538175; PubMed Central PMCID: PMC5457486.
17. Trelis M, Galiano A, Bolado A, Toledo R, Marcilla A, Bernal D. Subcutaneous injection of exosomes
reduces symptom severity and mortality induced by Echinostoma caproni infection in BALB/c mice.
International journal for parasitology. 2016; 46(12):799–808. Epub 2016/10/25. https://doi.org/10.1016/
j.ijpara.2016.07.003 PMID: 27590846.
18. Sotillo J, Pearson M, Potriquet J, Becker L, Pickering D, Mulvenna J, et al. Extracellular vesicles
secreted by Schistosoma mansoni contain protein vaccine candidates. International journal for parasi-
tology. 2016; 46(1):1–5. Epub 2015/10/16. https://doi.org/10.1016/j.ijpara.2015.09.002 PMID:
26460238.
19. Chaiyadet S, Krueajampa W, Hipkaeo W, Plosan Y, Piratae S, Sotillo J, et al. Suppression of mRNAs
encoding CD63 family tetraspanins from the carcinogenic liver fluke Opisthorchis viverrini results in dis-
tinct tegument phenotypes. Scientific reports. 2017; 7(1):14342. Epub 2017/11/01. https://doi.org/10.
1038/s41598-017-13527-5 PMID: 29084967; PubMed Central PMCID: PMC5662742.
20. Mekonnen GG, Pearson M, Loukas A, Sotillo J. Extracellular vesicles from parasitic helminths and their
potential utility as vaccines. Expert review of vaccines. 2018; 17(3):197–205. Epub 2018/01/23. https://
doi.org/10.1080/14760584.2018.1431125 PMID: 29353519.
21. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al. Tetraspanins on the surface
of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med. 2006; 12(7):835–
40. Epub 2006/06/20. https://doi.org/10.1038/nm1430 PMID: 16783371.
22. Laha T, Pinlaor P, Mulvenna J, Sripa B, Sripa M, Smout MJ, et al. Gene discovery for the carcinogenic
human liver fluke, Opisthorchis viverrini. BMC Genomics. 2007; 8:189. Epub 2007/06/26. https://doi.
org/10.1186/1471-2164-8-189 PMID: 17587442; PubMed Central PMCID: PMC1913519.
23. Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, et al. Comparative proteomics evaluation
of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human
blood plasma. Proteomics. 2013; 13(22):3354–64. Epub 2013/10/12. https://doi.org/10.1002/pmic.
201300282 PMID: 24115447.
24. Chaiyadet S, Smout M, Johnson M, Whitchurch C, Turnbull L, Kaewkes S, et al. Excretory/secretory
products of the carcinogenic liver fluke are endocytosed by human cholangiocytes and drive cell prolif-
eration and IL6 production. International journal for parasitology. 2015; 45(12):773–81. Epub 2015/07/
19. https://doi.org/10.1016/j.ijpara.2015.06.001 PMID: 26187786; PubMed Central PMCID:
PMC4912216.
Vaccination of hamster with extracellular vesicles and tetraspanins from liver fluke
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007450 May 28, 2019 14 / 15
25. Rosner B. Hypothesis Testing: Categorical Data/Estimation of Sample Size and Power for Comparing
Two Binomial Proportions. Fundamentals of biostatistics. 7 ed. Boston: Brooks/Cole, Cengage Learn-
ing; 2011.
26. Elkins DB, Haswell-Elkins M, Anderson RM. The epidemiology and control of intestinal helminths in the
Pulicat Lake region of Southern India. I. Study design and pre- and post-treatment observations on
Ascaris lumbricoides infection. Trans R Soc Trop Med Hyg. 1986; 80(5):774–92. Epub 1986/01/01.
https://doi.org/10.1016/0035-9203(86)90384-6 PMID: 3603617.
27. Jittimanee J, Sermswan RW, Kaewraemruaen C, Barta JR, Macinnes JI, Maleewong W, et al. Protec-
tive immunization of hamsters against Opisthorchis viverrini infection is associated with the reduction of
TGF-beta expression. Acta tropica. 2012; 122(2):189–95. Epub 2012/01/24. https://doi.org/10.1016/j.
actatropica.2012.01.010 PMID: 22266215.
28. Marcilla A, Trelis M, Cortes A, Sotillo J, Cantalapiedra F, Minguez MT, et al. Extracellular vesicles from
parasitic helminths contain specific excretory/secretory proteins and are internalized in intestinal host
cells. PLoS One. 2012; 7(9):e45974. Epub 2012/10/03. https://doi.org/10.1371/journal.pone.0045974
PMID: 23029346; PubMed Central PMCID: PMC3454434.
29. Cwiklinski K, de la Torre-Escudero E, Trelis M, Bernal D, Dufresne PJ, Brennan GP, et al. The Extracel-
lular Vesicles of the Helminth Pathogen, Fasciola hepatica: Biogenesis Pathways and Cargo Molecules
Involved in Parasite Pathogenesis. Mol Cell Proteomics. 2015; 14(12):3258–73. Epub 2015/10/22.
https://doi.org/10.1074/mcp.M115.053934 PMID: 26486420; PubMed Central PMCID: PMC4762619.
30. Zhu L, Liu J, Dao J, Lu K, Li H, Gu H, et al. Molecular characterization of S. japonicum exosome-like
vesicles reveals their regulatory roles in parasite-host interactions. Scientific reports. 2016; 6:25885.
Epub 2016/05/14. https://doi.org/10.1038/srep25885 PMID: 27172881; PubMed Central PMCID:
PMC4865838.
31. Nowacki FC, Swain MT, Klychnikov OI, Niazi U, Ivens A, Quintana JF, et al. Protein and small non-cod-
ing RNA-enriched extracellular vesicles are released by the pathogenic blood fluke Schistosoma man-
soni. Journal of extracellular vesicles. 2015; 4:28665. Epub 2015/10/08. https://doi.org/10.3402/jev.v4.
28665 PMID: 26443722; PubMed Central PMCID: PMC4595467.
32. Buck AH, Coakley G, Simbari F, McSorley HJ, Quintana JF, Le Bihan T, et al. Exosomes secreted by
nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. Nat Com-
mun. 2014; 5:5488. Epub 2014/11/26. https://doi.org/10.1038/ncomms6488 PMID: 25421927; PubMed
Central PMCID: PMC4263141.
33. Eichenberger RM, Ryan S, Jones L, Buitrago G, Polster R, Montes de Oca M, et al. Hookworm
Secreted Extracellular Vesicles Interact With Host Cells and Prevent Inducible Colitis in Mice. Frontiers
in immunology. 2018; 9:850. Epub 2018/05/16. https://doi.org/10.3389/fimmu.2018.00850 PMID:
29760697; PubMed Central PMCID: PMC5936971.
34. Merrifield M, Hotez PJ, Beaumier CM, Gillespie P, Strych U, Hayward T, et al. Advancing a vaccine to
prevent human schistosomiasis. Vaccine. 2016; 34(26):2988–91. Epub 2016/04/03. https://doi.org/10.
1016/j.vaccine.2016.03.079 PMID: 27036511.
35. Smout MJ, Laha T, Mulvenna J, Sripa B, Suttiprapa S, Jones A, et al. A granulin-like growth factor
secreted by the carcinogenic liver fluke, Opisthorchis viverrini, promotes proliferation of host cells.
PLoS pathogens. 2009; 5(10):e1000611. Epub 2009/10/10. https://doi.org/10.1371/journal.ppat.
1000611 PMID: 19816559; PubMed Central PMCID: PMC2749447.
36. Smout MJ, Sotillo J, Laha T, Papatpremsiri A, Rinaldi G, Pimenta RN, et al. Carcinogenic Parasite
Secretes Growth Factor That Accelerates Wound Healing and Potentially Promotes Neoplasia. PLoS
pathogens. 2015; 11(10):e1005209. Epub 2015/10/21. https://doi.org/10.1371/journal.ppat.1005209
PMID: 26485648; PubMed Central PMCID: PMC4618121.
37. Suttiprapa S, Sotillo J, Smout M, Suyapoh W, Chaiyadet S, Tripathi T, et al. Opisthorchis viverrini Prote-
ome and Host-Parasite Interactions. Advances in parasitology. 2018; 102:45–72. Epub 2018/11/18.
https://doi.org/10.1016/bs.apar.2018.06.002 PMID: 30442310.
38. de la Torre-Escudero E, Gerlach JQ, Bennett APS, Cwiklinski K, Jewhurst HL, Huson KM, et al. Surface
molecules of extracellular vesicles secreted by the helminth pathogen Fasciola hepatica direct their
internalisation by host cells. PLoS neglected tropical diseases. 2019; 13(1):e0007087. Epub 2019/01/
19. https://doi.org/10.1371/journal.pntd.0007087 PMID: 30657764; PubMed Central PMCID:
PMC6355031.
39. Andreu Z, Yanez-Mo M. Tetraspanins in extracellular vesicle formation and function. Frontiers in immu-
nology. 2014; 5:442. Epub 2014/10/04. https://doi.org/10.3389/fimmu.2014.00442 PMID: 25278937;
PubMed Central PMCID: PMC4165315.
Vaccination of hamster with extracellular vesicles and tetraspanins from liver fluke
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007450 May 28, 2019 15 / 15
© 2019 Chaiyadet et al. This is an open access article distributed under the
terms of the Creative Commons Attribution License:
http://creativecommons.org/licenses/by/4.0/(the “License”), which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited. Notwithstanding the ProQuest Terms
and Conditions, you may use this content in accordance with the terms of the
License.
